Evidence map›Paper›PMID 41312325›Full record

ArticleSkin health and disease2025

Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany.

Luise Heinrich, Thomas Birkner, Susanne Abraham, Sascha Gerdes, Tatjana Honstein, Sigrid Müller, Matthias Augustin, Inken Harder, Thomas Schaefer, Andreas Pinter and 17 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Skin health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Luise HeinrichCenter for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID https://orcid.org/0009-0002-2878-2019
Thomas BirknerCenter for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID https://orcid.org/0000-0002-1027-7295
Susanne AbrahamCenter for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID https://orcid.org/0000-0001-7457-6481
Sascha GerdesCenter for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0002-6667-7757
Tatjana HonsteinDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0009-0001-2897-964X
Sigrid MüllerCenter for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Matthias AugustinInstitute for Health Services Research in Dermatology Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0000-0002-4026-8728
Inken HarderCenter for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0002-3079-0440
Thomas SchaeferPractice Dr med. Thomas Schaefer and Dr med. Doreen Belz, Derma Koeln, Cologne, Germany.
Andreas PinterDepartment of Dermatology, Venereology and Allergology, Clinical Research, University Hospital, Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0002-1330-1502
Anne BongPractice Dr med. Anne Bong, Emmerich, Germany.
Jutta Ramaker-BrunkePractice 'Die Hautärzte' Braunschweig, Braunschweig, Germany.
Tilo BiedermannDepartment of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-5352-5105
Michael SticherlingDepartment of Dermatology, University, German Center for Immunotherapy, Erlangen, Germany.ORCID https://orcid.org/0000-0001-9396-3938
Hannah Gorriahn-MaiterthPractice Dermasana, Karlsruhe, Germany.
Knut SchäkelDepartment of Dermatology, University Hospital, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-6344-7799
Beate SchwarzPractice Dr med. Beate Schwarz, Langenau, Germany.
Sven QuistDermatology Clinic, Helix Medical Excellence Center Mainz, Mainz, Germany.ORCID https://orcid.org/0000-0002-9548-7813
Mohammad AsefiDermatology Study Center Hunsrück, Simmern, Germany.
Nicole AdlerHautärzte am Fastnachtsbrunnen, FÄ Nicole Adler, Mainz, Germany.
Maren StahlPractice Dr med. Maren Stahl, Osterode, Germany.
Michael Schulz-KiesowPractice Dr med. Michael Schulz-Kiesow and Dr med. Inken Reimers, Lübeck, Germany.
Florian SchenckDermatology Center, Hannover, Germany.
Thomas WerfelDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0001-6830-7672
Stephan WeidingerCenter for Inflammatory Skin Diseases, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID https://orcid.org/0000-0003-3944-252X
Annice HeratizadehDepartment of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.ORCID https://orcid.org/0000-0002-9231-9865
Jochen SchmittCenter for Evidence-Based Healthcare, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID https://orcid.org/0000-0003-0264-0960

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TREATgermany registry was set up in 2016. We provide results on long-term dupilumab therapy in adults with moderate and severe atopic dermatitis (AD) in a routine care setting. The analysis cohort of 294 patients is one of the largest cohorts with 2-year follow-up data on treatment effects of dupilumab obtained from an AD registry to date. We report the Harmonising Outcome Measures for Eczema (HOME) core outcome set. The Eczema Area Severity Index (EASI) 75 and EASI 90 response rates for patients on treatment at month 24 were 78.8% and 51.2%, respectively.

Identifiers

PMID41312325
PMCPMC12648515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.